Structural requirements for inhibition of the neuronal nitric oxide synthase (NOS-I): 3D-QSAR analysis of 4-oxo- and 4-amino-pteridine-based inhibitors

Journal of Medicinal Chemistry

Volumn 45, Issue 14, 2002, Pages 2923-2941

  Matter, Hans ^a   Kotsonis, Peter ^a,c   Klingler, Otmar ^a   Strobel, Hartmut ^a   Fröhlich, Lothar G ^a,b   Frey, Armin ^a,b   Pfleiderer, Wolfgang ^a,d   Schmid, Harald H H W ^a,b  

^a SANOFI AVENTIS DEUTSCHLAND GMBH   (Germany)

^b JUSTUS LIEBIG UNIVERSITY GIESSEN   (Germany)

^c Novatis Inst for Medical Sciences   (United Kingdom)

^d UNIVERSITY OF KONSTANZ   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOPTERIDINE DERIVATIVE; 4 OXOPTERIDINE DERIVATIVE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE INHIBITOR; TETRAHYDROBIOPTERIN; UNCLASSIFIED DRUG;

ARTICLE; DEGENERATIVE DISEASE; DIMERIZATION; ENZYME INHIBITION; INFLAMMATION; QUANTITATIVE STRUCTURE ACTIVITY RELATION; SEPSIS;

ENZYME INHIBITORS; ISOENZYMES; MODELS, MOLECULAR; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE TYPE I; PROTEIN BINDING; PTERIDINES; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0037019267     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm020074g     Document Type: Article

References (112)

1. Isolation of nitric oxide synthetase, a calmodulin-requiring enzyme
2. Nitric oxide synthase structure and mechanism
3. Arginine is a physiological precursor of endothelium-derived nitric oxide
4. Vascular endothelial cells synthesize nitric oxide from L-arginine
5. Mammalian nitric oxide synthases
6. Nitric oxide: Physiology, pathophysiology, and pharmacology
7. NO at Work
8. Evidence supporting the proposal that endothelium-derived relaxing factor is nitric oxide
9. Nitric oxide accounts for the biological activity of endothelium-derived relaxing factor
10. Endothelium-derived relaxing factor produced and released from artery and vein is nitric oxide
11. Structure of nitric oxide synthase oxygenase dimer with pterin and substrate
12. Crystal structure of constitutive endothelial nitric oxide synthase: A paradigm for pterin function involving a novel metal center
13. Nitric oxide: A new paradigm for second messengers
14. Nitric oxide synthases: Properties and catalytic mechanism
15. Purification and characterization of human NO synthase
16. Purification of a soluble isoform of guanylyl cyclase-activating-factor synthase
17. The inhibition of the constititive and inducible nitric oxide synthase isoforms by indazole agents
18. Nitric oxide and focal cerebral ischemia: Multiplicity of actions and diverse outcome. Cerebrovasc
19. The role of glutamate neuritoxicity in hypoxic-ischemic neuronal death
20. Role of neuronal nitric oxide in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced dopaminergic neurotoxicity
21. Characterization of the novel nitric oxide synthase inhibitor 7-nitro indazole and related indazoles: Antinociceptive and cardiovascular effects
22. The role of nitric oxide in migraine pain
23. Calmodulin-dependent endothelium-derived relaxing factor/nitric oxide synthase activity is present in the particulate and cytosolic fractions of bovine aortic endothelial cells
24. Purification and characterization of particulate endothelium-derived relaxing factor synthase from cultured and native bovine aortic endothelial cells
25. Nitric oxide and macrophage function
26. Inducible nitric oxide synthase and its product nitric oxide, a small molecule with complex biological activities
27. Nitric oxide synthases in mammals
28. Structural characterization of nitric oxide synthase isoforms reveals striking active-site conservation
29. The structure of nitric oxide synthase oxygenase domain and inhibitor complexes
30. Protective and pathological roles of nitric oxide in endotoxin shock
31. Approaches toward selective inhibition of nitric oxide synthase
32. NY-methyl-L-arginine functions as an alternate substrate and mechanism-based inhibitor of nitric oxide synthase
33. γ-nitroarginine
34. δ-iminoethyl-L-orthinine as an irreversible inhibitor of nitric oxide synthase in phagocytic cells
35. ω-Nitroarginine-containing dipeptide amides. Potent and highly selective inhibitors of neuronal nitric oxide synthase
36. Reduced amide bond peptidomimetics. (4S)-N-(4-amino-5-[aminoalkyl]-aminopentyl)-N′-nitroguanidines, potent and highly selelctive inhibitors of neuronal nitric oxide synthase
37. S-alkyl-L-thiocitrullines
38. Inhibitors of nitric oxide synthases
39. N-Phenylamidines as selective inhibitors of human neuronal nitric oxide synthase: Structure-activity studies and demonstration of in vivo activity
40. A new class of selective and potent inhibitors of neuronal nitric oxide synthase
41. Anti-Pterins as tools to characterize the function of tetrahydrobiopterin in NO synthase
42. Inhibition of neuronal nitric oxide synthase by 4-amino pteridine derivatives: Structure-activity relationship of antagonists of (6R)-5,6,7,8-tetrahydrobioperin cofactor
43. Development of novel 4-oxo pteridine antagonists of (6R)-5,6,7,8-tetrahydrobiopterin in neuronal nitric oxide synthase
44. Comparative molecular field analysis (CoMFA). 1. Effect of shape on binding of steroids to carrier proteins
45. Comparative molecular field analysis (CoMFA). 2. Towards its use with 3D-structural databases
46. Molecular similarity indices in a comparative analysis (CoMSIA) of drug molecules to correlate and predict their biological activity
47. Multivariate structure-activity relationship between data from a battery of biological tests and an ensemble of structure descriptors: The PLS method
48. Notes on the history and nature of Partial Least Squares (PLS) modelling
49. Cross-validatory estimation of the number of component in factor and principal component models
50. Computer-intensive methods for statistics
51. Crossvalidation, bootstrapping and partial least squares compared with multiple regression in conventional QSAR studies
52. Validation of the General Purpose Tripos 5.2 Force Field
53. Iterative partial equalization of orbital electronegativity: A rapid access to atomic charges
54. Development and use of quantum mechanical molecular models. 76. AM1: A new general purpose quantum mechanical molecular model
55. The Protein Data Bank: A computer-based archival file for macromolecular structures
56. A computational procedure for determining energetically favorable binding sites on biologically important macromolecules
57. Fast generation of molecular surfaces from 3D data fields with enhanced 'marching cube' algorithm
58. MOLCAD - Interactive molecular computer graphics on high-performance computers
59. A new approach to the display of local lipophilicity/hydrophilicity mapped on molecular surfaces
60. Atomic physicochemical parameters for three-dimensional structure-directed quantitative structure-activity relationships. 1. Partition coefficients as a measure of hydrophobicity
61. Atomic physicochemical parameters for three-dimensional structure-directed quantitative structure-activity relationships. 4. Additional parameters for hydrophobic and dispersive interactions and their application for an automated superposition of certain naturally occurring nucleoside antibiotics
62. Focusing of electric fields in the active site of copper-zinc superoxide dismutase: Effects of ionic strength and amino acid modification
63. A rapid finite difference algorithm, utilizing successive overrelaxation to solve the Poisson-Boltzmann equation
64. Calculating the electrostatic potential of molecules in solution: Method and error assessment
65. Solvent-accessible surfaces of proteins and nucleic acids
66. Analytical molecular surface calculation
67. Knowledge-based protein modeling and design
68. Knowledge-based modeling of homologous proteins. Part I: Three-dimensional frameworks derived from the simultaneous superposition of multiple structures
69. Knowledge based modeling of homologous proteins. Part II: Rules for the conformations of substituted side chains
70. An evaluation of the performance of an automated procedure for comparative modelling of protein tertiary structure
71. A genetic algorithm for flexible molecular overlay and pharmacophore elucidation
72. A new procedure for improving the predictiveness of CoMFA models and its application to a set of dihydrofolate reductase inhibitors
73. Improved alignment by weighted field fit in CoMFA of histamine H2 receptor agonistic imidazolylpropylguanidines
74. An alternative method for the alignment of molecular structures: Maximizing electrostatic and steric overlap
75. Recommendations for CoMFA studies and 3D QSAR publications
76. CoMFA: Scope and limitations
77. The developing practice of comparative molecular field analysis
78. Extending the trend vector: The trend matrix and sample-based partial least squares
79. The probability of chance correlation using partial least squares (PLS)
80. PLS Validation by progressive scrambling
81. Structure-based identification of a ricin inhibitor
82. Entropy in bisubstrate enzymes: Proposed role of an alternate site in chaperoning substrate into, and products out of, thymidylate synthase
83. Analysis of tetrahydrobiopterin and its role in nitric oxide synthesis
84. Random or rational design? Evaluation of diverse compound subsets from chemical structure databases
85. Implementing drug screening programs using molecular similarity methods
86. Simulation analysis of experimental design strategies for screening random compounds as potential new drugs and agrochemicals
87. Three-dimensional quantitative structure-activity relationship analyses using comparative molecular field analysis and comparative molecular similarity indices analysis to elucidate selectivity differences of inhibitors binding to trypsin, thrombin, and factor Xa
88. Method for fast flexible ligand superposition
89. Prediction of properties from simulations: Free energies of solvation in hexadecane, octanol, and water
90. Prediction of drug solubility from Monte Carlo simulations
91. Chemometric rationalization of the structural and physicochemical basis for selective cyclooxygenase-2 inhibition: Toward more specific ligands
92. Selective inhibitors of cyclooxygenase-2 (COX-2)
93. Affinity and selectivity of matrix metalloproteinase inhibitors: A chemometrical study from the perspective of ligands and proteins
94. A novel strategy for improving ligand selectivity in receptor-based drug design
95. Pteridine-Based Photoaffinity Probes for Nitric Oxide Synthase and Aromatic Amino Acid Hydroxylases
96. Pteridine XXXI. Synthese und Eigenschaften blockierter 7,8-Dihydro-pterine
97. Pfleiderer Synthesis and properties of 6-substituted 2,4-diaminopteridines and pterins
98. Pteridines. Part XCVII. Synthesis and properties of 6-thioxanthopterin and 7-thioisoxanthopterin
99. Thiol dependence of nitric oxide synthase